HDAC1

HDAC1
Name	Histone deacetylase 1
Other names	HDAC1
Location	Nucleus
Family	Histone deacetylases class I
Gene	HDAC1

HDAC1 HDAC1 is a human class I histone deacetylase enzyme that removes acetyl groups from lysine residues on histone and non-histone proteins, influencing chromatin structure and transcriptional regulation. It operates in multiprotein assemblies to coordinate gene repression and DNA repair and is implicated in development, cell cycle control, and oncogenesis. HDAC1 has been studied across molecular biology, clinical oncology, and pharmacology contexts by research groups and pharmaceutical companies worldwide.

Introduction

HDAC1 was cloned and characterized in studies involving researchers at institutions such as National Institutes of Health, Harvard University, Stanford University, Massachusetts Institute of Technology, and University of Cambridge. Early functional links were made through work tied to model organism labs at Harvard Medical School, University of California, Berkeley, and Cold Spring Harbor Laboratory. Its biochemical role was integrated into chromatin research informed by landmark projects like the Human Genome Project and initiatives at the European Molecular Biology Laboratory. HDAC1 emerged as a focal point in studies connecting chromatin modulators to pathways described in reports from organizations such as the American Association for Cancer Research and the European Society for Medical Oncology.

Structure and Biochemical Properties

The HDAC1 polypeptide contains conserved catalytic motifs characteristic of class I enzymes defined during comparative analyses from groups at Scripps Research Institute and Max Planck Institute. Structural insights have been provided by laboratories using techniques developed at Brookhaven National Laboratory, European Synchrotron Radiation Facility, and Argonne National Laboratory to resolve active site architecture and zinc coordination. Biochemical assays standardized in protocols from Cold Spring Harbor Protocols and repositories like the Protein Data Bank detailed substrate specificity and kinetics. Studies leveraging cryo-EM and X-ray crystallography from collaborations with teams at University of Oxford and ETH Zurich illustrated interactions between HDAC1 and peptide substrates, informing inhibitor design in partnerships with pharmaceutical groups at Novartis, Pfizer, and GlaxoSmithKline.

Biological Functions and Mechanisms

HDAC1 participates in transcriptional repression pathways characterized in seminal work at Yale University, Johns Hopkins University, and University of California, San Francisco. It modulates chromatin compaction linked to cell cycle control reported by investigators associated with Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. HDAC1 contributes to DNA damage response pathways intersecting with research from National Cancer Institute and regulatory networks described by teams at University College London and McGill University. Functional studies in developmental biology have been reported from The Salk Institute, Karolinska Institute, and University of Tokyo, connecting HDAC1 activity to differentiation programs and lineage specification.

Regulation and Post-translational Modifications

Post-translational modifications of HDAC1 including phosphorylation, acetylation, ubiquitination, and SUMOylation were characterized in work from laboratories at University of California, San Diego, Columbia University, and University of Pennsylvania. Kinase signaling links were reported involving pathways studied at Imperial College London and UCSF Medical Center, while ubiquitin–proteasome regulation was detailed by teams at Stanford Medicine and Vanderbilt University Medical Center. Proteostasis and turnover mechanisms were further explored in studies affiliated with Rockefeller University and Weizmann Institute of Science, highlighting cross-talk with signaling frameworks described at Memorial Sloan Kettering Cancer Center.

Role in Disease and Clinical Implications

Aberrant HDAC1 activity has been implicated in oncogenic programs described in clinical studies from Mayo Clinic, Cleveland Clinic, and multicenter trials coordinated by National Cancer Institute. Altered expression patterns were reported in tumor profiling efforts by consortia such as The Cancer Genome Atlas and research networks at European Organisation for Research and Treatment of Cancer. HDAC1 involvement in neurodegenerative disorders and psychiatric conditions has been examined in collaborations including National Institute of Mental Health, Stanford Neurosciences Institute, and Johns Hopkins Neuroscience. Associations with inflammatory and metabolic disorders were investigated in cohorts studied by Karolinska Institute and Mount Sinai Health System.

Interactions and Complexes

HDAC1 forms core components of multiprotein assemblies characterized by groups at Cold Spring Harbor Laboratory, University of Cambridge, and Institut Pasteur. Notable complexes and interaction partners were elucidated in studies from University of California, Irvine, Harvard Medical School, and Yale School of Medicine including co-repressor assemblies analyzed in collaborations with Massachusetts General Hospital and Dana-Farber Cancer Institute. Proteomic mapping performed by teams at European Bioinformatics Institute and Max Planck Institute for Biochemistry integrated HDAC1 into networks studied by systems biology groups at Broad Institute and Sloan Kettering Institute.

Therapeutic Targeting and Inhibitors

HDAC1 is a target for small-molecule inhibitors developed by pharmaceutical research divisions at Merck & Co., Bristol-Myers Squibb, and Eli Lilly and Company and evaluated in clinical trials overseen by organizations such as Food and Drug Administration and European Medicines Agency. Compounds originally characterized in academic–industry partnerships at Dana-Farber Cancer Institute and University of Oxford progressed to trials reported in journals associated with American Society of Clinical Oncology and European Society for Medical Oncology. Combination therapy strategies involving epigenetic modulators were pursued in consortia that include National Cancer Institute cooperative groups and translational centers at Moffitt Cancer Center.

Category:Proteins